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Abstract
Elevated N-methyl-D-aspartate receptor (NMDAR) activity is linked to central sensitization and 
chronic pain. However, NMDAR antagonists display limited therapeutic potential due to their 
adverse side effects. Novel approaches targeting the NR2B-PSD95-nNOS complex to disrupt 
signaling pathways downstream of NMDARs show efficacy in preclinical pain models. Here, we 
evaluated the involvement of interactions between neuronal nitric oxide synthase (nNOS) and the 
nitric oxide synthase 1 adaptor protein (NOS1AP) in pronociceptive signaling and neuropathic 
pain. TAT-GESV, a peptide inhibitor of the nNOS-NOS1AP complex, disrupted the in vitro 
binding between nNOS and its downstream protein partner NOS1AP but not its upstream protein 
partner postsynaptic density 95 kDA (PSD95). Putative inactive peptides (TAT-cp4GESV, TAT-
GESVΔ1) failed to do so. Only the active peptide protected primary cortical neurons from 
glutamate/glycine-induced excitotoxicity. TAT-GESV, administered intrathecally (i.t.), suppressed 
mechanical and cold allodynia induced by either the chemotherapeutic agent paclitaxel or a 
traumatic nerve injury induced by partial sciatic nerve ligation (PSNL). TAT-GESV also blocked 
the paclitaxel-induced phosphorylation at Ser15 of p53, a substrate of p38 MAPK. Finally, TAT-
GESV (i.t.) did not induce NMDAR-mediated motor ataxia in the rota-rod test and did not alter 
basal nociceptive thresholds in the radiant heat tail-flick test. These observations support the 
hypothesis that anti-allodynic efficacy of an nNOS-NOS1AP disruptor may result, at least in part, 
from blockade of p38 MAPK-mediated downstream effects. Our studies demonstrate, for the first 
time, that disrupting nNOS-NOS1AP protein-protein interactions attenuates mechanistically 
distinct forms of neuropathic pain without unwanted motor ataxic effects of NMDAR antagonists.
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1. Introduction
Excessive N-methyl-D-aspartate receptor (NMDAR) activity is important for central 
sensitization and development and maintenance of chronic pain. However, NMDAR 
antagonists have limited therapeutic value due to incomplete efficacy and unwanted side 
effects [36; 55]. An alternative approach is to disrupt protein-protein interactions 
downstream of NMDARs that mediate signaling cascades critical for central sensitization. 
Protein-protein interactions between the NR2B subunit of NMDAR, the scaffolding protein 
postsynaptic density 95 kDa (PSD95) and the enzyme neuronal nitric oxide synthase 
(nNOS), referred to as the NR2B-PSD95-nNOS interface, are involved in neuropathological 
conditions including stroke/ischemia, pain and depression. We and others showed that 
disrupting PSD95-nNOS [8; 17; 27] and NR2B-PSD95 [13] interactions suppresses pain at 
doses that lack adverse side effects in rodents [44].
In addition to PSD95, nNOS interacts with nitric oxide synthase 1 adaptor protein 
(NOS1AP), also known as Carboxy-terminal PDZ ligand of nNOS (CAPON) [24]. Binding 
of nNOS to NOS1AP occurs through a class III PDZ-PDZ interaction between the canonical 
PDZ (postsynaptic density 95, PSD95; discs large, Dlg; zonula occludens-1, ZO-1) of nNOS 
(amino acid (a.a.) 11–98) and both the stabilizing C-terminal tail and indispensable internal 
ExF motif (a.a. 429–431) of NOS1AP [24; 28; 30; 48]. Interactions between nNOS and 
NOS1AP are implicated in neuropathological conditions including stroke, anxiety and 
schizophrenia, and disrupting these interactions is neuroprotective [6; 9; 29; 49; 57]. 
NMDAR-dependent association of nNOS-NOS1AP activates p38 mitogen-activated protein 
kinase (p38 MAPK) by recruiting mitogen-activated protein kinase kinase 3 (MKK3) to the 
complex [15; 29; 38]. Activation of p38 MAPK is observed in preclinical pain models, 
suggesting that inhibiting p38 MAPK activation may interrupt pronociceptive signaling [11; 
25; 26; 31; 58]. Downstream p38 MAPK substrates (e.g. tumor protein p53 (p53)) may 
underlie cytotoxic and inflammatory effects associated with p38MAPK-activation [65]. 
However, whether nNOS-NOS1AP interactions are involved in pronociceptive signaling and 
pathological pain is unknown.
To investigate involvement of nNOS-NOS1AP in pathological pain, we used TAT-GESV, a 
peptide inhibitor of the consensus binding sequence for the core PDZ domain of nNOS [29; 
40]. TAT-GESV attenuates NMDAR-induced cytotoxicity and is neuroprotective in an 
ischemia model [29; 40]. We evaluated the potency and specificity of TAT-GESV, in 
comparison to putative inactive peptides (TAT-cp4GESV, TAT-GESVΔ1), in disrupting 
nNOS-NOS1AP interactions using AlphaScreen binding assays. The ability of TAT-GESV 
to disrupt PSD95-nNOS binding was evaluated to assess selectivity. We also verified that 
TAT-GESV suppresses glutamate/glycine-induced excitotoxicity in primary cortical neurons. 
Based upon the known critical roles of the peptide ligand terminal valine in target 
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recognition, we predicted that terminal valine deletion (using TAT-GESVΔ1) would prevent 
the otherwise active peptide from both disrupting nNOS-NOS1AP binding and suppressing 
neuropathic pain. We tested the hypothesis that intrathecal (i.t.) TAT-GESV, but not TAT-
GESVΔ1, would suppress mechanical and cold hypersensitivity in mechanistically distinct 
models of neuropathic pain and investigated potential mechanisms underlying efficacy of 
nNOS-NOS1AP disruption in lumbar spinal cord of paclitaxel-treated mice. Lastly, we 
evaluated whether nNOS-NOS1AP disruption lacked unwanted side effects of NMDAR 
antagonists.
2. Materials and methods
2.1 Drugs and chemicals
Peptides were obtained from the laboratory of Dr. Michael Courtney (Turku Centre for 
Biotechnology, University of Turku and Åbo Academy University, Finland) or purchased 
from GenicBio (Shanghai, China), GeneCust (Dudelange, Luxembourg) or Peptide 2.0 
(Chantilly, VA) with at least 95% purity: L-TAT (GRKKRRQRRR); L-TAT-GESV 
(GRKKRRQRRRYAGQWGESV); L-TAT-GESVΔ1 (GRKKRRQRRRYAGQWGES): 
lacking the last C-terminal Val residue; L-TAT-cp4GESV 
(GRKKRRQRRRGESVYAGQW): the C-terminal GESV tetrapeptide was placed between 
the TAT sequence and the N-terminal YAGQW pentapeptide. All peptides were dissolved in 
PBS for AlphaScreen and cell death assays and dissolved in saline (Aquilite System; 
Hospira, Inc, Lake Forest, IL) for in vivo experiments. MK-801 was purchased from Sigma 
Aldrich (St. Louis, MO) and dissolved in DMSO for the cell death assay and dissolved in 
saline for in vivo experiments. ZL006, used here in AlphaScreen as a positive control [27], 
was obtained from Dr. Ganesh Thakur (Northeastern University, MA) and dissolved in 
DMSO.
2.2 Protein purification
Purification of glutathione S-transferase (GST), His-tagged PSD95, nNOS and NOS1AP is 
previously described [27; 29]. In short, PSD951-392, containing the PDZ domain that binds 
nNOS, was expressed as His-tagged using pET-30a. nNOS1-299, containing the core PDZ 
domain that binds NOS1AP and the β-finger that binds to PDZ2 of PSD95 but lacking the 
catalytic domain, was expressed as GST- or His-tagged using pGEX 4T-1 or pET-30a, 
respectively. GST-NOS1AP400-506, containing the internal ExF internal motif and C-
terminal tail that is recognized by the core PDZ domain of nNOS, was expressed as GST-
tagged.
2.3 AlphaScreen assay
AlphaScreen assays were set up and performed as previously described by our group [27]. 
AlphaScreen is a bead-based binding assay which uses donor beads, coated with glutathione, 
which recognize GST-tagged purified protein, and acceptor beads, coated with Nickel-
chelate, which recognize His-tagged purified protein. When donor beads are excited with 
680 nm light, phthalocyanine containing donor beads convert ambient oxygen into singlet 
oxygen. When two proteins are in close proximity (i.e. within 200 nm), thioxene derivatives 
containing acceptor beads receive singlet oxygen and emit light at 520–620 nm which can 
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then be read with an EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA). 
Briefly, binding between nNOS and NOS1AP was set up using His-nNOS1-299 and GST-
NOS1AP400-506 proteins. AlphaScreen Ni Chelate Acceptor beads (PerkinElmer, Waltham, 
MA) and AlphaScreen Glutathione Donor beads (PerkinElmer, Waltham, MA) were 
sequentially added, and incubated for 1 h with each addition. The reaction was carried out in 
a 40 μl final volume using 96-well ½ area plates in 1X PBS containing BSA (1mg/mL) and 
Tween-20 (0.1%). An EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA) 
equipped with AlphaScreen optical detection module was used to read plates. Titration was 
performed to determine 50% binding (or Kd) between His-nNOS1-299 and GST-
NOS1AP400-506 (0–200 nM each). To test disruption of the protein-protein binding by short 
peptide inhibitors, the reaction was carried out using concentrations of His-nNOS1-299 and 
GST-NOS1AP400-506 that lead to 50% of maximum binding. Inhibitors or vehicle (i.e. serial 
dilutions were performed with PBS or DMSO in parallel with inhibitors) were added to the 
protein pairs at the beginning of the experiments. To confirm specificity of disruption, 
control experiments tested the ability of the short peptide inhibitors to disrupt binding 
between purified His-PSD951-392 and GST-nNOS1-299 using the PSD95-nNOS inhibitor 
ZL006 as a positive control. All the short peptides used in this experiment were dissolved in 
1X PBS. ZL006 was dissolved in DMSO (>99% purity, Sigma-Aldrich, St. Louis, MO). 
Peptides and ZL006 were prepared as 10 or 20 mM stocks and subsequent dilutions were 
made from this stock for use in each assay. In each assay, 1X PBS and DMSO, the vehicles 
used to dissolve the peptides and small molecules, respectively, were also subsequently 
diluted in the same manner as the test compounds. Peptides or ZL006 ranging in 
concentrations from 0–200 μM were used. The readout of each point from EnSpire® 
Multimode Plate Reader was normalized into %AlphaScreen Signal Counts with the 
following equation: (signal detected with drug treatment at X concentration/signal detected 
without drug treatment)*100. Each data point represents the means derived from all 
replicates generated from at least two independent assays performed on separate days. IC50 
was determined by non-linear regression with equation of log (inhibitor) vs. normalized 
response.
2.4 Embryonic cortical neuron culture
Timed-pregnant Sprague Dawley rats were obtained from Envigo (Indianapolis, IN) and, 
following equilibration in the animal facility, were sacrificed via decapitation after halothane 
administration to obtain embryonic pups for cell culture experiments. Cortices derived from 
E18-E19 Sprague-Dawley rat pups were harvested according to approved IACUC guidelines 
as previously described [3; 21]. Pelleted cortical cells were resuspended in neuronal growth 
(Neurobasal) media containing 2% NuSerum (BD Biosciences, San Jose, CA), 2% NS21, 
penicillin (10 units/mL), streptomycin (10 μg/mL), and L-glutamine (29.2 μg/mL) at a 
density of 2.5 million cells/mL and seeded on poly-D-lysine (50 μg/mL)- coated 15 mm 
coverslips (German glass Number 0). Forty-eight hours after plating, cultures were treated 
with 5-fluor-2′-deoxyuridine (1.5 μg/mL) and uridine (3.5 μg/mL) to minimize glial 
contamination [27].
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2.5 Excitotoxic stimulation and cell death assay
Neurons (DIV 7–8) were pretreated with TAT-GESV (10 μM), TAT-cp4GESV (10 μM), the 
NMDAR antagonist MK-801 (20 μM) or vehicle for 20 minutes at 37°C and subsequently 
treated with excitotoxic stimulants 100 μM glutamate/10 μM glycine for 1 h at 37 °C [3]. 
Following treatment, stimulation media was removed and coverslips were washed with fresh 
neuronal growth media and the neurons were incubated for 24 h. The coverslips were 
washed the next day in PBS and stained using Live/Dead Cytotoxicity/Viability kit 
(Molecular Probes, Eugene, OR). Following staining, the coverslips were washed in PBS 
and immediately imaged using a Nikon Ti-E inverted microscope (100X magnification). 
Each coverslip was imaged in three different fields using a Texas Red filter to detect 
cytotoxicity and a FITC filter to detect viable cells. Cells were quantified using the 
automated counting software Nikon Elements 3.0 [27].
2.6 Subjects
Adult C57BL/6J male mice, weighing 23–33g (Jackson Laboratory, Bar Harbor, ME) were 
used in these experiments. Adult mice were housed at Indiana University Bloomington in a 
temperature-controlled facility (73 ± 2 °F, 45% humidity under a 12-hour light/dark cycle). 
The mice received standard rodent chow and water ad libitum. All experimental procedures 
were approved by Bloomington Institutional Animal Care and Use Committee of Indiana 
University and followed guidelines of the International Association for the Study of Pain. 
The experimenter was blinded to the experimental condition in all in vivo studies.
2.7 Paclitaxel-induced neuropathic pain
Paclitaxel (Tecoland Corporation, Irvine, CA) was dissolved in a vehicle consisting of a 
1:1:4 ratio of cremophor EL (Sigma-Aldrich, St. Louis, MO): 95% ethanol (Sigma-Aldrich): 
saline (Aquilite System; Hospira, Inc, Lake Forest, IL). Mice were injected with either the 
cremophor-based vehicle (i.e. vehicle) or paclitaxel (4 mg/kg, i.p.) on day 0, 2, 4, and 6 
following initiation of paclitaxel dosing (16 mg/kg i.p. cumulative dose). Responsiveness to 
mechanical and cold stimulation was assessed before initiation of paclitaxel or vehicle 
dosing (Baseline, day 0) and during development and maintenance phases of paclitaxel-
induced hypersensitivity as previously described [27]. Sensitivity to mechanical and cold 
stimulation was assessed on days 4, 7, 11 and 15 following initial paclitaxel/vehicle dosing.
2.8 Dose response of nNOS-NOS1AP peptide inhibitors in paclitaxel-induced neuropathic 
pain model
Peptides or saline were administered using the method of direct intrathecal injection 
described by Fairbanks [16] and Wilcox [22]. Briefly, direct lumbar puncture was performed 
on conscious mice with a 30-gauge, 0.5 inch sterile disposable PrecisionGlide needle (BD, 
Franklin Lake, NJ) connected to a 50 μl Luer-hub Hamilton syringe (Hamilton Robotics, 
Reno, NV). The needle was inserted at the midline between the hip bones which 
corresponds to the level of the cauda equina. Puncture of the dura was indicated by a “tail-
flick” or formation of an “S” shape tail as described by Fairbanks [16]. No motor 
impairment was observed in any of the animals receiving intrathecal injections. The 
injection volume was 5 μl. All intrathecal injections were performed by a single 
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experimenter with extensive prior training marked by greater than 90% success rate (i.e. 
resulting in “tail flick” or “S”-shaped tail) prior to initiation of experiments described in the 
present study. When paclitaxel-induced neuropathy was stable (i.e. beginning on day 16 post 
initiation of paclitaxel dosing), mice were randomly divided into six groups and injected 
with saline (i.t.), TAT-GESV (1.25, 2.5, 5 or 10 nmol i.t) or TAT-GESVΔp1 (10 nmol i.t). 
Mice receiving the cremophor-based vehicle were treated concurrently with the same 
peptide treatments to ascertain whether changes in mechanical or cold responsiveness 
required the presence of the neuropathic pain state. Responsiveness to mechanical and cold 
stimulation was assessed in the same animals beginning 10 minutes following i.t. injection 
of peptide or saline.
2.9 Time course of nNOS-NOS1AP peptide inhibitors in paclitaxel-induced neuropathic 
pain model
A separate group of paclitaxel-treated mice were randomly divided into three groups and 
injected intrathecally with saline (i.t.), an efficacious dose of TAT-GESV (5 nmol i.t.) or 
TAT-GESVΔp1 (5 nmol i.t.) on day 16 following initiation of paclitaxel dosing. 
Responsiveness to mechanical and cold stimulation was assessed starting at 10 minutes after 
peptide injection and re-evaluated at 30, 60, 90, and 150 minutes post injection.
2.10 Assessment of mechanical allodynia
Withdrawal thresholds (g) to mechanical stimulation were measured in duplicate for each 
paw using an electronic von Frey anesthesiometer supplied with a 90-g semi-flexible probe 
(IITC Life Science, Woodland Hills, CA) as described previously [14; 18]. Both paclitaxel- 
and PSNL-evoked allodynia were evaluated with this method.
2.11 Assessment of cold allodynia
Responsiveness to cold was assessed by applying an acetone bubble (~5–6 μl) (Sigma 
Aldrich, St. Louis, MO) to the plantar surface of the hind paw through the hub of a 1 cc 
syringe with no needle. Time spent reacting to acetone stimulation (i.e., raising shaking, 
licking or stepping) was measured in triplicate for each paw [14; 43; 51]. Both paclitaxel- 
and PSNL-evoked allodynia were evaluated with this method.
2.12 Partial sciatic nerve ligation model of traumatic nerve injury
Prior to surgery, baseline responses to mechanical and cold stimulation were assessed. On 
the day of surgery, the right thigh of the animal was shaved and aseptic surgical procedures 
were followed. Under light anesthesia with isoflurane, the sciatic nerve was pierced with 8-0 
silk black braided suture (Ethicon, Somerville, NJ) so that 1/3 to ½ of the right sciatic nerve 
of the animal could be isolated and tightly ligated with the suture as previously described to 
induce the partial sciatic nerve ligation (PSNL) model of neuropathic pain. Seven days post-
surgery, responsiveness to mechanical and cold stimulation was reassessed. Animals were 
then divided into six groups receiving i.t. injections of saline, MK-801 (5 nmol i.t.), TAT-
GESV (2.5, 5, and 10 nmol i.t.) or TAT-GESVΔp1 (10 nmol i.t.). Mechanical paw 
withdrawal thresholds and duration of time spent reacting to cold stimulation was evaluated 
10 minutes following i.t. injection. The same mice subsequently received repeated once 
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daily intrathecal injections with the same saline, MK-801 (5 nmol i.t.), TAT-GESV (10 nmol 
i.t.) or TAT-GESVΔp1 (10 nmol i.t.) treatments delivered acutely for a total of 8 consecutive 
days. Mechanical and cold sensitivity were re-evaluated on days 4 and 8 following the initial 
intrathecal injection.
2.13 Rota-rod test
Motor performance was assessed as described previously using an accelerating Rota-rod 
(IITC Life Science) (4–40 rpm with cutoff time of 300 seconds). Mice were trained for two 
days and, on the third day, the baseline descent latency was measured. On the fourth day, 
mice were intrathecally injected with saline (i.t.), MK-801 (5, 10 or 25 nmol i.t.), TAT-
GESV (10 nmol i.t.), or TAT-GESVΔ1 (10 nmol i.t.). Ten minutes after injection, the mice 
were placed on the accelerating rota-rod and the latency for the animals to fall off the 
rotating drum was recorded. On the baseline and post-drug testing day, each mouse was 
required to pass a criterion (i.e. ability to walk on the rotating drum for 30 seconds) in order 
to advance to assessment of drug effects. Mice (n = 4) that did not pass criteria did not 
receive any pharmacological manipulations and were not included in the study.
2.14 Radiant heat tail flick
The latency of tail withdrawal from radiant heat was assessed using an IITC Tail Flick 
Analgesia Meter (Model 336) (IITC Life Science Inc., Woodland Hills, CA). Cutoff time 
was set to 10 seconds to prevent damage to the tail of the mice. Baseline withdrawal 
latencies were measured in triplicate prior to pharmacological manipulations (i.e. 
approximately one day before the experimental day). The intensity of the radiant heat was 
set to obtain a baseline tail-flick latency of approximately 5 seconds. On the experimental 
day, mice were injected acutely with saline (i.t.), MK-801 (5–25 nmol i.t.), TAT-GESV (10 
nmol i.t.) or TAT-GESVΔ1 (10 nmol i.t) 10 minutes prior to tail flick assessment. Tail flick 
latencies were evaluated in duplicate following pharmacological manipulations using a six-
minute interstimulation interval.
2.15 Generation of lumbar spinal cord samples for western blot analysis
A separate group of mice were injected with saline (i.t.), TAT-GESV (5 nmol i.t.) or TAT-
GESVΔ1 (5 nmol i.t.) on day 16 following initial paclitaxel or vehicle treatment. Twenty 
minutes following intrathecal injection, at the time point where maximum anti-allodynic 
efficacy was observed in the paclitaxel model (as determined previously), mice were rapidly 
decapitated without anesthesia and the lumbar enlargement was rapidly dissected, fast frozen 
in isopentane precooled on dry ice and stored at −80°C until use. Lumbar spinal cord tissue 
was processed for pp38MAPK, pp53 and pERK1/2 analysis using western blot protocols 
described below.
2.16 Immunoblotting for pERK1/2, and pp53
Mouse lumbar spinal cords were homogenized in RIPA buffer (25mM Tris, 150mM NaCl, 
0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4) supplemented with 1 mM 
DTT, 10 μg/ml protease inhibitors (aprotinin, leupeptin, and pepstatin A), 0.1 mg/ml PMSF, 
and precleared at 20,000 g for 10 minutes at 4 °C. Total protein was measured using a Bio-
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Rad DC Protein Assay Kit (Bio-rad, Hercules, CA). The supernatant of each sample was 
boiled in SDS-PAGE sample loading buffer for 10 minutes at 95 °C and analyzed by 
Western blotting.
For Western blot analysis, samples were loaded onto SDS-PAGE gel and transferred to 
nitrocellulose membrane. Nitrocellulose membranes were blocked with TBS-T with 5% 
milk added. Antibodies used were as follows: Phospho-p53 (Ser 15) (D4S1H) rabbit mAb 
(#12571, Cell Signaling Technology, Danvers, MA.), Anti-ACTIVE® MAPK (pTEpY) 
rabbit polyclonal Ab (#V8031, Promega, Madison, WI.), p44/42 MAPK (Erk 1/2) rabbit 
polyclonal Ab (#9102, Cell Signaling Technology), THE™ beta Actin mouse mAb 
(#A00702, Pascataway, NJ), goat anti-rabbit-HRP (#sc-2030, Santa Cruz, Santa Cruz, CA) 
and goat anti-mouse-HRP (#sc-2005, Santa Cruz, Santa Cruz, CA). Blots were developed 
using SuperSignal West Femto Maximum Sensitivity substrate (ThermoFisher Scientific 
Waltham, MA) and pre-flashed (Sensitize unit, GE) X-ray films (Amersham Hyperfilm 
ECL, GE) were exposed to the blots. Images were quantified using Image J Gel Analyzer 
(Background corrected profile analysis).
2.17 Statistical Analysis
Data analyses were performed according to principles outlined by Motulsky [35]. All in 
vitro data was analyzed using GraphPad Prism version 7.0 (GraphPad Software, La Jolla, 
CA). Dose response curves derived from AlphaScreen data were analyzed by non-linear 
regression using the equation of an inhibitor (log) vs. normalized response to generate IC50 
values. Impact of drug treatments on glutamate/glycine-induced cell death was analyzed by 
One-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc tests. Results 
from immunoblotting experiments were analyzed by One-way ANOVA followed by either 
Bonferroni’s multiple comparison tests (for pp53) or Bonferroni’s post hoc tests (for pERK). 
Bonferroni’s multiple comparison tests, which use the mean square result from the overall 
ANOVA table, were performed using GraphPad Prism 7.0. The multiple comparisons tests 
enable comparison of preselected pairs of means (i.e. TAT-GESV vs. saline and TAT-GESV 
vs. TAT-GESVΔ1) to obtain more statistical power to detect differences by making a more 
limited set of comparisons [35], thereby minimizing chances of obtaining a Type II error. In 
vivo data were analyzed using SPSS (SPSS Inc., an IBM company, Chicago, IL, USA). In 
vivo data involving more than two sets of data and only one variable (i.e. different drugs) 
were analyzed using one-way ANOVA followed by Bonferroni’s post hoc tests. In vivo data 
involving two variables (e.g. compounds and time) were analyzed by either repeated 
measures two-way ANOVA (i.e. when behavioral measures were evaluated in the same 
animals at different times) or by two-way ANOVA (i.e. when behavioral measures were 
evaluated in different groups of animals), followed by Bonferroni’s post hoc tests in each 
case. The impact of surgery (PSNL/sham) on mechanical and cold sensitivity relative to 
baseline (pre-surgery) was evaluated prior to intrathecal injections using two-way repeated 
measures ANOVA followed by Bonferroni’s post hoc tests when these designs involved 
comparisons of more than two independent groups. Planned comparisons between two 
groups were performed using unpaired or paired sample t-tests, as appropriate for between 
group or within group comparisons, respectively. P < 0.05 was considered statistically 
significant.
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3. Results
3.1 TAT-GESV specifically disrupts the nNOS-NOS1AP complex in an in vitro AlphaScreen 
binding assay
TAT-GESV disrupted protein-protein interactions between His-nNOS1-299 and GST-
NOS1AP400-506 in an AlphaScreen biochemical binding assay with an IC50 of 8.47 μM 
(Figure 1A). TAT and PBS did not interfere with the binding between His-nNOS1-299 and 
GST-NOS1AP400-506 (Figure 1A). In addition to TAT- GESVΔ1, we also included TAT-
cp4GESV, which did not disrupt NMDA activation-induced cell death in our previous work 
[29], as a negative control. Neither TAT-cp4GESV nor TAT-GESVΔ1 disrupted the 
interactions between His-nNOS1-299 and GST-NOS1AP400-506 in AlphaScreen (Figure 1A). 
Moreover, TAT-GESV did not disrupt the binding between purified GST-nNOS1-299 and 
His-PSD951-392 (Figure 1B), suggesting that the active peptide did not disrupt the 
interactions between PDZ2 of PSD95 and the β-finger flanking the nNOS core PDZ domain. 
However, the PSD95-nNOS small molecule inhibitor ZL006 reliably disrupted the binding 
between purified GST-nNOS1-299 and His-PSD951-392 with IC50 of 12.76 μM (Figure 1B), 
similar to what was described previously by our group [27].
3.2 TAT-GESV protects against glutamate/glycine-induced cell-death
To verify that disruption of nNOS-NOS1AP interaction inhibits NMDAR-dependent 
excitotoxicity, we characterized the efficacy of TAT-GESV in protecting against glutamate-
induced neuronal cell death. In primary cortical neurons, addition of glutamate (100 μM)/
glycine (10 μM) for 1 h produced cell death that differed between the experimental 
treatments [F4,13= 75.376; p < 0.0001, one-way ANOVA] (Figure 2). Cell death was higher 
in primary cortical neurons pre-treated with vehicle that were exposed to glutamate/glycine 
compared to the control (no glutamate/glycine) condition [p < 0.001, Bonferroni’s post hoc 
test]. Pretreatment of cortical neurons with either the nNOS-NOS1AP disruptor TAT-GESV 
(10 μM) or the NMDAR antagonist MK-801 (20 μM) attenuated glutamate/glycine-induced 
cell death relative to vehicle [p < 0.001 for each comparison, Bonferroni’s post hoc test]. 
Cell death was lower in primary cortical neurons pre-treated with the active peptide TAT-
GESV compared to the inactive peptide TAT-cp4GESV [p < 0.001, Bonferroni’s post hoc 
test]). TAT-cp4GESV did not protect against glutamate/glycine-induced cell-death relative to 
vehicle [p = 1, Bonferroni’s post hoc test]. Cell death was lower in primary cortical neurons 
pre-treated with MK-801 compared to all other groups exposed to glutamate/glycine [p < 
0.01 for each comparison, Bonferroni’s post hoc test]. Glutamate/glycine-induced cell death 
was higher in primary cortical neurons pre-treated with either vehicle or TAT-cp4GESV 
compared to all other groups [p < 0.001 for each comparison, Bonferroni’s post hoc test] 
(Figure 2).
3.3 Intrathecal TAT-GESV dose-dependently reduces paclitaxel-induced neuropathic pain
We treated mice with paclitaxel or its vehicle and evaluated whether intrathecal 
administration of TAT-GESV would suppress paclitaxel-induced neuropathic pain (see 
Figure 3A). Prior to treatment with paclitaxel or vehicle, there were no differences between 
groups in paw withdrawal thresholds to mechanical stimulation [p = 0.68, unpaired t-test; 
Figure 3B] or duration of responsiveness to cold stimulation [p = 0.421, unpaired t-test; 
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Figure 3C]. Paclitaxel decreased mechanical paw withdrawal thresholds, mechanical 
responsiveness differed across test days and the effects of paclitaxel were time-dependent 
[F1,70 = 265.136; p < 0.0001 (treatment); F4,280 = 84.744; p < 0.0001 (time); F4,280 = 90.28; 
p < 0.0001(interaction); two-way repeated measures ANOVA; Figure 3B]. Paclitaxel also 
increased the duration of responding to cold, cold responsiveness differed across test days 
and the effects of paclitaxel on cold responsiveness were also time dependent [F1,70 = 
117.271; p < 0.0001 (treatment); F4,280 = 79.966; p < 0.0001 (time); F4,280 = 69.587; p < 
0.0001(interaction); two-way repeated measures ANOVA; Figure 3C]. Paclitaxel lowered 
mechanical paw withdrawal thresholds and increased cold response times relative to vehicle 
starting on day 7 and these behavioral hypersensitivities remained ongoing on day 15 post 
injection [mechanical and cold: p < 0.0001 from day 7–15, Bonferroni’s post hoc test] 
(Figure 3B,C).
On day 16, mice received direct intrathecal injections of saline, TAT-GESV, or TAT-
GESVΔ1 (Figure 3A). Prior to intrathecal injections (day 16), paclitaxel reduced mechanical 
thresholds relative to baseline (pre-injection) levels [p < 0.0001, paired sample t-test; Figure 
3D] whereas the cremophor-based vehicle had no such effect [p = 0.975, paired sample t-
test; Figure 3D]. Similarly, mechanical paw withdrawal thresholds were lower in paclitaxel-
treated compared to vehicle-treated mice on day 16, prior to intrathecal injections [p < 
0.0001, unpaired t-test; Figure 3D]. Intrathecal TAT-GESV treatment elevated mechanical 
paw withdrawal thresholds, the doses differed from each other and the interaction between 
dose and treatment was significant [F1,50 = 123.426, p < 0.0001 (treatment); F4,50 = 13.267, 
p < 0.0001 (dose); F4,50 = 12.474, p < 0.0001 (interaction): Two-way ANOVA]. TAT-GESV 
(5 nmol, i.t.) restored paw withdrawal thresholds in paclitaxel-treated mice to the level 
observed in vehicle-treated mice receiving the same dose [p = 0.654, Bonferroni’s post hoc 
test] (Figure 3D). Lower doses of TAT-GESV (1.25 and 2.5 nmol) did not normalize paw 
withdrawal thresholds to levels observed in vehicle-treated mice receiving the same doses [p 
= 0.0001, Bonferroni’s post hoc test] (Figure 3D).
In paclitaxel-treated mice, TAT-GESV (10 nmol, i.t) increased paw withdrawal thresholds 
[F2,15 = 13.823, p < 0.001; One-way ANOVA] compared to either saline (i.t.) [p = 0.001, 
Bonferroni’s post hoc test] or TAT-GESVΔ1 [p = 0.003, Bonferroni’s post hoc test] 
treatments. Effects of TAT-GESVΔ1 (10 nmol, i.t.) [p = 1, Bonferroni’s post hoc test] did not 
differ from saline (i.t.) treatment (Figure 3F).
Prior to intrathecal injections (day 16), paclitaxel increased duration of responding to cold 
stimulation relative to baseline levels [p < 0.0001, paired sample t-test] whereas the 
cremophor-vehicle had no such effect [p = 0.264, paired sample t-test] (Figure 3E). 
Intrathecal administration of TAT-GESV reduced cold responses, the doses differed from 
each other and the interaction between dose and treatment was significant [F1,50 = 72.183, p 
< 0.0001(treatment); F4,50 = 7.15, p < 0.0002 (dose); F4,50 = 6.09, p < 0.0005 (interaction): 
Two-way ANOVA]. Paclitaxel-induced cold responsiveness was dose-dependently reduced 
by TAT-GESV and the 5 nmol (i.t.) dose normalized cold response times to levels observed 
in vehicle-treated mice receiving the same dose [p = 0.215, Bonferroni’s post hoc test] 
(Figure 3E). Other doses of TAT-GESV (1.25, 2.5 and 10 nmol) failed to normalize cold 
response times compared to vehicle-treated mice receiving the same doses [p < 0.05 for each 
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comparison, Bonferroni’s post hoc test] (Figure 3E). Effects of the 5 nmol and 10 nmol 
doses of TAT-GESV on either mechanical or cold responsiveness did not differ from each 
other [p = 1, Bonferroni’s post hoc test] (Figure 3D, E).
In paclitaxel-treated mice, TAT-GESV (10 nmol i.t.) reduced cold response times [F2,15 = 
4.241, p < 0.05; One-way ANOVA] relative to saline [p = 0.039, Bonferroni ‘s post hoc test] 
but not TAT-GESVΔ1 (10 nmol, i.t.) [p = 0.172, Bonferroni‘s post hoc test] (Figure 3G). 
However, effects of TAT-GESVΔ1 did not differ from saline [p = 1, Bonferroni’s post hoc 
test].
3.4 Time course of TAT-GESV-induced suppression of paclitaxel-induced mechanical 
allodynia
The duration of anti-allodynic efficacy of TAT-GESV was evaluated in a separate set of 
paclitaxel-treated mice. Intrathecal drug treatments altered paclitaxel-induced mechanical 
hypersensitivity (Figure 4). No main effect of time was observed and the interaction between 
intrathecal treatment and time was significant [F2,12 = 22.252, p < 0.001 (group); F5,60 = 
1.426, p = 0.228 (time); F10,60 = 3.584, p < 0.002 (interaction); Two-way repeated measures 
ANOVA] (Figure 4). The maximally efficacious dose of TAT-GESV (5 nmol, i.t.) increased 
paw withdrawal thresholds compared to either saline [p < 0.0001, Bonferroni’s post hoc test] 
or TAT-GESΔ1 [p = 0.003, Bonferroni’s post hoc test] throughout the observation interval, 
whereas effects of TAT-GESΔ1 did not differ from saline [p = 0.154, Bonferroni’s post hoc 
test]. TAT-GESV reliably increased mechanical paw withdrawal thresholds in paclitaxel-
treated mice relative to the saline-treated group from 10 to 60 min post-injection [10–60 
min: p < 0.009 for all comparisons, Bonferroni’s post hoc test] (Figure 4). Paw withdrawal 
thresholds were higher in mice receiving the active compared to the inactive peptide from 
10–30 min post injection [10 min: p < 0.04; 30 min: p < 0.0002; Bonferroni’s post hoc test] 
(Figure 4). By contrast, TAT-GESVΔ1 (5 nmol, i.t.) did not alter paclitaxel-induced 
mechanical responsiveness relative to saline (i.t.) [p > 0.363 for all time points, Bonferroni’s 
post hoc test] (Figure 4).
3.5 Intrathecal TAT-GESV reduces paclitaxel-induced p53 activation but not ERK1/2 
activation in mouse lumbar spinal cord
Phosphorylated p38 MAPK (p-p38 MAPK, used as a measure of activated p38 MAPK) was 
not reliably detected in mouse lumbar spinal cord tissue at the time point when the tissue 
was collected (unpublished observations). We asked, therefore, whether lumbar spinal cord 
levels of phosphorylation of p53 at serine 15 (pSer15-p53), a residue at p53 selectively 
phosphorylated by activated p38 MAPK, could be more abundant and, therefore, detectable 
under conditions in which the active kinase was not. Using the same tissue used for p-
p38MAPK detection, we compared pSer15-p53 levels in lumbar spinal cords derived from 
paclitaxel-treated mice receiving TAT-GESV (5 nmol i.t.), TAT-GESVΔ1 (5 nmol i.t.) or 
saline (i.t.) with vehicle-treated mice receiving saline (i.t.); the overall ANOVA approached 
significance [F3,16 = 2.851, p = 0.07; One-way ANOVA; Figure 5A,C]. Bonferroni’s 
multiple comparison test, which uses the mean square error term from this same ANOVA 
table [35], nonetheless, revealed that TAT-GESV reduced pSer15-p53 levels compared to 
saline [p < 0.05] but not compared to TAT-GESVΔ1 [p = 0.16] treatment. We also asked 
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whether pSer15-p53 levels were increased by paclitaxel treatment in a manner blocked by 
spinal disruption of nNOS-NOS1AP interactions. Paclitaxel increased lumbar spinal cord 
levels of pSer15-p53 in a TAT-GESV-sensitive manner [F2,12 = 17.447, p < 0.0003, One-way 
ANOVA]; pSer15-p53 levels were increased in samples derived from paclitaxel-treated 
compared to vehicle-treated mice [p = 0.002, Bonferroni’s post hoc test] and TAT-GESV (5 
nmol i.t.) also reduced paclitaxel-induced elevations in pSer15-p53 levels [p = 0.0004, 
Bonferroni’s post hoc test]. Lumbar spinal cord pSer15-p53 levels did not differ in samples 
derived from cremophor vehicle-treated mice that received saline (i.t.) and paclitaxel-treated 
mice receiving TAT-GESV (i.t.) [p = 1, Bonferroni’s post hoc test], suggesting that TAT-
GESV effectively restored pSer15-p53 levels to normal (Figure 5A,C). We also evaluated 
phosphorylation levels of another MAPK group, ERK1/2, because these kinases can also 
phosphorylate p53 at Ser15 [37; 41]. Paclitaxel elevated pERK1/2 levels [F3,16 = 60.34; p < 
0.0001, One-way ANOVA] in the same lumbar spinal cord samples evaluated for pSer-p53 
levels relative to those derived from cremophor-vehicle treated mice similarly receiving 
saline (i.t.) [p < 0.0001, Bonferroni’s post hoc test]. However, in samples derived from 
paclitaxel-treated mice, neither TAT-GESV nor TAT-GESVΔ1 (5 nmol, i.t.) altered pERK1/2 
elevation relative to saline (i.t.) [p > 0.4, Bonferroni’s post hoc test] (Figure 5B,D). These 
observations suggest that the TAT-GESV-induced blockade of pSer15-p53 phosphorylation 
induced by paclitaxel in lumbar spinal cord is independent of the ERK1/2 pathway (Fig. 
5A–D).
3.6 Intrathecal TAT-GESV attenuates neuropathic pain induced by partial sciatic nerve 
ligation
To determine whether TAT-GESV suppresses neuropathic pain induced by a surgically-
induced traumatic nerve injury, we subjected mice to unilateral PSNL or sham surgery (see 
Figure 6A). Unilateral PSNL reduced mechanical paw withdrawal thresholds and increased 
duration of responding to cold in the injured (ipsilateral) paw relative to baseline (pre-
surgery) levels [mechanical: p < 0.0001; cold: p < 0.0001, paired sample t-test] (Figure 
6B,C). By contrast, sham surgery did not alter responsiveness to mechanical or cold 
stimulation relative to baseline (pre-surgery) levels [Mechanical: p = 0.159; Cold: p = 0.416, 
paired sample t-test] (Figure 6B,C).
Post-injection paw withdrawal thresholds differed between PSNL and sham-operated 
groups, the TAT-GESV doses differed from each other and the interaction between dose and 
surgical treatment was significant [F1,56 = 24.532, p < 0.0001 (group); F3,56 = 3.694, p = 
0.017 (dose); F3,56 = 3.673, p = 0.017 (interaction); Two-way ANOVA] (Figure 6B). TAT-
GESV (5 and 10 nmol i.t.) elevated mechanical paw withdrawal thresholds in the ipsilateral 
paw of PSNL-operated mice, normalizing responsiveness to levels observed in sham-
operated mice receiving the same doses [5 nmol: p = 0.261; 10 nmol: p = 0.474, 
Bonferroni’s post hoc test] (Figure 6B). By contrast, ipsilateral paw withdrawal thresholds 
were lower in PSNL-treated mice receiving vehicle [0 nmol; p < 0.0001, Bonferroni’s post 
hoc test] or the low dose of TAT-GESV (2.5 nmol i.t.) [p = 0.001, Bonferroni’s post hoc test] 
compared to sham-operated mice receiving the same treatments (Figure 6B).
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Post-injection cold response times also trended to differ between PSNL- and sham-operated 
groups, the TAT-GESV doses differed from each other and the interaction between dose and 
surgical treatment was significant [F1,56 = 3.067, p = 0.085 (group); F3,56 = 6.28, p = 0.001 
(dose); F3,56 = 5.426. p = 0.002 (interaction); Two-way ANOVA] (Figure 6C). TAT-GESV, 
at doses of 2.5, 5 and 10 nmol (i.t.) [p > 0.072 for each comparison, Bonferroni’s post hoc 
test], normalized cold responsiveness to levels comparable to those observed in the sham-
operated mice receiving the same doses (Figure 6C). By contrast, cold responsiveness in the 
ipsilateral paw was higher in PSNL-treated compared to sham-operated mice receiving 
saline (i.t.) [0 nmol; p < 0.0001, Bonferroni’s post hoc test; Figure 6C].
In PSNL-treated groups, TAT-GESV (10 nmol, i.t.) increased paw withdrawal thresholds 
[F2,19 = 5.938, p = 0.01; One-way ANOVA] compared to either saline (i.t.) treatment or 
TAT-GESVΔ1 (10 nmol i.t.) treatment [p < 0.05 for each comparison, Bonferroni’s post hoc 
test] (Figure 6D). By contrast, paw withdrawal thresholds did not differ between PSNL-
treated groups receiving TAT-GESVΔ1 (10 nmol, i.t.) or saline (i.t.) [p = 1, Bonferroni’s post 
hoc test] (Fig. 6D).
In PSNL-operated mice, TAT-GESV (10 nmol i.t.) similarly reduced cold-response times 
[F2,19 = 10.633, p = 0.001; One-way ANOVA] compared to either saline (i.t.) [p < 0.01, 
Bonferroni’s post hoc test] or TAT-GESVΔ1 (10 nmol) [p = 0.003, Bonferroni’s post hoc 
test] treatment (Figure 6E). By contrast, cold responsiveness did not differ between PSNL-
treated groups receiving TAT-GESVΔ1 (10 nmol, i.t.) and saline (i.t.) [p = 1, Bonferroni’s 
post hoc test] (Figure 6E).
Surgical manipulations did not alter behavioral responding in the contralateral (non-
operated) paw and no significant main effects or interactions were observed in the paw 
contralateral to PSNL or sham surgery for either stimulus modality [Mechanical: p = 0.168 
(group); p = 0.179 (interaction); Cold: p = 0.941 (group); p = 0.289 (interaction); Two-way 
repeated measures ANOVA] (Figure 6F,G). Moreover, neither TAT-GESV nor TAT-GESVΔ1 
altered mechanical or cold responsiveness in the paw contralateral to PSNL or sham surgery 
[Mechanical: p = 0.065 (dose); p = 0.882 (drug); p = 0.065 (interaction); Cold: p = 0.39 
(dose); p = 0.491 (drug); p = 0.882 (interaction); Two-way ANOVA] (Figure 6F,G).
3.7 Impact of chronic intrathecal dosing with TAT-GESV on PSNL-induced mechanical and 
cold allodynia
Prior to intrathecal injections, PSNL surgery decreased mechanical paw withdrawal 
thresholds and increased cold response times relative to baseline [mechanical: F1,24 = 
209.884, p < 0.0001; cold: F1,24 = 44.14, p < 0.0001; Two-way repeated measures ANOVA; 
Figure 7A,B]. There were no differences between groups prior to intrathecal treatments and 
the interaction between drug treatment and surgical condition was not significant 
[mechanical: p = 0.303 (group), p = 0.625 (interaction); cold: p = 0.811 (group) p = 0.619 
(interaction); Two-way repeated measures ANOVA].
Post-injection mechanical paw withdrawal thresholds also differed between groups and 
across injection days and effects of intrathecal treatments were injection day dependent 
[F3,19 = 21.892, p < 0.0001 (group); F3,57 = 16.401, p < 0.0001 (day); F9,57 = 3.581, p = 
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0.001 (interaction); Two-way repeated measures ANOVA] (Figure 7A). Both TAT-GESV 
and MK-801 increased mechanical paw withdrawal thresholds relative to either saline (i.t.) 
or TAT-GESVΔ1 (i.t.) treatment throughout the chronic dosing period [p < 0.002 for each 
comparison, Bonferroni’s post hoc test] (Figure 7A). Effects of TAT-GESV did not differ 
from MK-801 (i.t.) and effects of TAT-GESVΔ1 (i.t.) did not differ from saline (i.t.) [p = 1 
for each comparison; Bonferroni’s post hoc test] (Figure 7A). In mice subjected to PSNL, 
both TAT-GESV (i.t.) and MK-801 (i.t.) similarly increased mechanical paw withdrawal 
thresholds relative to saline (i.t.) or TAT-GESVΔ1 (i.t.) with sustained efficacy [day 4–8: p < 
0.001 for each comparison; Bonferroni’s post hoc test] (Figure 7A).
In mice subjected to PSNL, cold response times differed between treatment groups and 
across injection days but this latter effect was not dependent upon drug treatment [F3,19 = 
4.696, p = 0.013 (group); F3,57 = 3.359; p = 0.025 (day); F9,57 = 1.684, p = 0.114 
(interaction), respectively; Two-way repeated measures ANOVA] (Figure 7B). In PSNL 
groups, TAT-GESV (i.t.) reduced cold responsiveness relative to saline (i.t.) treatment 
throughout the observation interval [p < 0.05; Bonferroni’s post hoc test], whereas 
reductions in cold sensitivity produced by MK801 approached significance [p = 0.072; 
Bonferroni’s post hoc test]. TAT-GESVΔ1 (i.t.) did not reliably alter cold responsiveness 
relative to saline (i.t.), MK-801 (i.t.) or TAT-GESV (i.t.) across the observation interval [p > 
0.25 for each comparison; Bonferroni’s post hoc test] (Figure 7B).
In mice subjected to PSNL, repeated intrathecal dosing did not alter mechanical paw 
withdrawal thresholds or cold response times in the contralateral (unoperated) paw 
[mechanical: p = 0.332 (group); p = 0.621 (day); p = 0.92 (interaction); Cold: p = 0.123 
(group); p = 0.171 (day); p = 0.559 (interaction); Two-way repeated measures ANOVA] 
(Figure 7C,D). In sham-operated mice, injection day impacted mechanical and cold 
responsiveness on the operated side [mechanical: F3,57 = 6.292, p = 0.001 (day); Cold: F3,57 
= 3.376, p = 0.024 (day); Two-way repeated measures ANOVA], but these effects were not 
related to intrathecal treatments because no main effect of drug treatment was observed and 
the interaction between drug treatment and injection day was not significant [mechanical: p 
= 0.2 (group); p = 0.124 (interaction); cold: p = 0.649 (group); p = 0.927 (interaction); Two-
way repeated measures ANOVA] (Figure 7E,F). Similarly, in mice subjected to sham 
surgeries, mechanical and cold responsiveness in the contralateral paw did not differ 
between groups or across injection days [mechanical: p = 0.12 (group); p = 0.254 (day); p = 
0.837 (interaction); cold: p = 0.831 (group); p = 0.106 (day); p = 0.77 (interaction); Two-
way repeated measures ANOVA] (Figure 7G,H).
3.8 Intrathecal TAT-GESV does not produce motor ataxia
Rota-rod descent latencies differed between groups in an injection-dependent manner [F5,28 
= 2.785; p = 0.037 (interaction); Two-way repeated measures ANOVA] (Figure 8). The high 
dose of MK-801 (25 nmol i.t.) lowered rota-rod descent latencies relative to all other post-
injection groups [p < 0.05 for all comparisons; Bonferroni’s post hoc test]. There were no 
main effects of either injection phase or drug treatment [F1,28 = 0.001, p = 0.981(injection 
phase); F5,28 = 2.216, p = 0.081(group); Two-way repeated measures ANOVA] (Figure 8).
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3.9 Intrathecal TAT-GESV administration did not alter radiant heat tail flick latency
Tail-flick latencies did not differ between groups (Figure 9). Injections produced a modest 
but reliable increase in tail-flick latencies but this effect was independent of drug treatment 
because the interaction between injection phase and treatment group was not significant 
[F5,28 = 0.746, p = 0.595 (group); F1,28 = 5.405, p = 0.028 (injection phase); F5,28 = 0.615, p 
= 0.689 (interaction); Two-way repeated measures ANOVA]. Neither pre-injection tail-flick 
latencies [p = 0.879. One-way ANOVA] nor post-injection tail-flick latencies [p = 0.504, 
One-way ANOVA] differed between groups (Figure 9).
3.10 Summary of the effects of nNOS-NOS1AP disruption on pathological pain
A conceptual model summarizing the proposed effect of the membrane-permeant nNOS-
NOS1AP disruptor TAT-GESV on NMDAR signaling in neuropathic pain is shown in Figure 
10.
Discussion
Here, we show that disrupting nNOS-NOS1AP interactions at the spinal level suppresses 
mechanistically distinct forms of neuropathic pain. Moreover, the nNOS-NOS1AP protein-
protein interface may be implicated in pronociceptive signaling. We and others have shown 
that the NMDAR-PSD95-nNOS complex is a possible target for drug development of anti-
hyperalgesic and anti-allodynic agents that lack unwanted side effects associated with 
NMDAR antagonists [8; 13; 17; 27; 44]. Disrupting protein-protein interactions downstream 
of NR2B produces therapeutic efficacy [8; 17; 27; 34; 56]. Tat-NR2B9c, a peptide 
comprising the last 9 a.a. of NR2B, shows therapeutic efficacy for stroke and neuropathic 
pain [1; 13; 20]. Moreover, among other Tat-NR2B9c interacting proteins, neuroprotective 
effects only resulted from suppressing the expression of PSD95 or nNOS, suggesting that 
NMDAR-PSD95-nNOS is critical in mediating NMDAR-dependent excitotoxicity [12].
Our group previously showed that NMDAR activation increases association of nNOS with 
its adaptor protein, NOS1AP, and this increased association leads to cell death through a p38 
MAPK-dependent mechanism that is blocked by TAT-GESV, L-TAT-NR2B9c and IC87201 
[29]. These findings suggest that p38 MAPK activation is linked to NMDAR activation and 
is blocked by disrupting NR2B-PSD95-nNOS-NOS1AP complexes. nNOS-NOS1AP 
disruption blocked NMDAR-mediated p38 MAPK activation without altering NO 
production, whereas disruption of NR2B-PSD95 and PSD95-nNOS reduced NO production 
[1; 7; 17; 23; 29; 39]. Thus, blockade of p38 MAPK activation may underly the 
neuroprotective efficacy of TAT-GESV. Therefore, we hypothesized that blocking the 
activation of NMDAR-mediated p38 MAPK activation through nNOS-NOS1AP disruption 
would represent a more functionally selective attenuation of neurotoxicity and 
pronociceptive signaling compared to targeting the upstream PSD95-nNOS or NR2B-PSD95 
protein-protein interactions. We, therefore, evaluated whether disrupting nNOS-NOS1AP 
interactions could attenuate neuropathic pain and represent a potential therapeutic target for 
drug development of anti-allodynic agents.
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We demonstrated the ability of the peptide inhibitor TAT-GESV to disrupt nNOS-NOS1AP 
interactions through a direct mechanism using AlphaScreen. TAT-GESV, but not the putative 
inactive peptides TAT-cp4GESV and TAT-GESVΔ1, disrupted the binding between purified 
nNOS and NOS1AP. Our results are consistent with the previous finding derived from co-
immunoprecipitation because TAT-GESV competes with NOS1AP for the C-terminal ligand 
binding site on nNOS PDZ, destabilizing nNOS-NOS1AP interactions [29; 30]. Moreover, 
deletion of the C-terminal valine in TAT-GESVΔ1, by eliminating the strong hydrogen-bond 
and hydrophobic interactions with the nNOS PDZ domain, could account for our 
observation that TAT-GESVΔ1 failed to disrupt nNOS-NOS1AP binding.
We also verified the specificity of TAT-GESV in disrupting the nNOS-NOS1AP complex 
using AlphaScreen. TAT-GESV disrupted the binding between nNOS and NOS1AP but not 
between PSD95 and nNOS whereas the PSD95-nNOS inhibitor ZL006 reliably blocked the 
latter interaction [27]. nNOS interacts with PSD95 through its β-finger, while nNOS binds to 
NOS1AP at a site distinct from that of PSD95 [47; 48; 50]. Moreover, TAT-GESV is a 
consensus ligand (G-D/E-X-V) for the class III PDZ domain and does not correspond to the 
class I motif, conforming to D/E-T/S-X-V, with selectivity for PDZ domains like PDZ2 of 
PSD95 [29; 40; 47; 48]. These observations support the hypothesis that TAT-GESV disrupts 
nNOS-NOS1AP but not PSD95-nNOS interactions.
TAT-GESV has been shown to attenuate NMDA-induced cell death and block NMDA-
induced activation of p38 MAPK [29]. We previously showed that small molecule PSD95-
nNOS disruptors protect against glutamate-induced cell death in primary cortical neurons 
[27]. In the current study, TAT-GESV- or MK-801-pretreated cortical neurons were protected 
from glutamate/glycine-induced cell death whereas a putative inactive peptide had no effect. 
Collectively, our results confirm that TAT-GESV penetrates cells to disrupt NMDAR 
activation-mediated excitotoxicity [29].
The present studies demonstrate that disrupting nNOS-NOS1AP interactions with TAT-
GESV suppresses behavioral hypersensitivities in two mechanistically distinct models of 
neuropathic pain: a model of toxic neuropathy induced by the chemotherapeutic agent 
paclitaxel and a model of traumatic nerve injury induced by PSNL. Chemotherapeutic 
agents can produce distal axonal injury and partial degeneration of the intraepidermal nerve 
fibers by affecting the excitability and survival of neurons through multiple mechanisms 
including disruption of axonal transport, increased ion channel activity, neuronal injury and 
inflammation [4; 19; 42; 54]. By contrast, PSNL results from direct injury and possible 
contributions from sympathetic sprouting and is regarded as having less of an inflammatory 
component than other peripheral nerve injury models [5]. In our studies, intrathecal 
administration of TAT-GESV, but not the inactive peptide TAT-GESVΔ1, reversed 
mechanical and cold hypersensitivities in both neuropathic pain models. These observations 
support our hypothesis that disrupting nNOS-NOS1AP interactions is a viable anti-allodynic 
strategy for suppressing neuropathic pain.
We previously reported that PSD95-nNOS inhibitors IC87201 and ZL006, administered 
acutely, are efficacious in suppressing paclitaxel-induced neuropathic pain [27]. Here we 
show that paclitaxel-induced mechanical and cold allodynia is attenuated by both acute and 
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chronic TAT-GESV (i.t.), whereas basal nociceptive responses were not affected. Thus, 
nNOS-NOS1AP disruption eliminated aberrant mechanical and cold hypersensitivities 
induced by paclitaxel without altering normal nociception. Disrupting nNOS-NOS1AP 
interactions with nNOS1-99 does not alter the enzymatic activity of nNOS or the production 
of NO whereas TAT-GESV blocked phosphorylation of p38 MAPK in cultured cells [6; 29]. 
We, therefore, collected lumbar spinal cords derived from paclitaxel-treated mice to 
determine whether TAT-GESV (i.t.) could attenuate p38 MAPK activation associated with a 
pathological pain state. Entire lumbar enlargements derived from paclitaxel-treated mice 
were used for parallelism with the in vivo studies and to enable us to eliminate variability in 
dissections. This sampling method would, nonetheless, be expected to dilute our signal 
because both dorsal and ventral horns were processed together in a single sample. We were 
unable to reliably detect p38 MAPK activity in these samples. Consistent with our finding, 
lumbar spinal cords derived from paclitaxel-treated rats did not exhibit increases in various 
microglia markers or phosphorylated p38 MAPK expression but exhibited increases in the 
astrocyte marker GFAP in spinal dorsal horn [53]. However, other studies have shown that 
NMDA administration directly to the spinal cord induced p38 MAPK activation, likely in 
microglia and a small subpopulation of neurons in rats [45]. In addition, administration of 
substance P and formalin in rats induced p38 MAPK activation in microglia 5 minutes post 
treatment but the activation returned to basal levels after 20 minutes [46]. Thus, the 
possibility remains that p38 MAPK is activated transiently in lumbar spinal cord after 
inflammatory insults or toxic challenge with paclitaxel. We, nonetheless, were able to 
demonstrate that phosphorylation of a selective substrate site for p38 MAPK, p53 at Ser15, a 
transcriptional regulator linked to cellular stress and chronic inflammation, was reliably 
increased in paclitaxel-treated lumbar spinal cords in a TAT-GESV-dependent manner. We 
found increases in pSer15-p53 level after paclitaxel compared to vehicle-treatment; this 
increase in pSer15-p53 expression was reduced in mice injected with TAT-GESV (i.t.). 
Moreover, ERK1/2, another upstream regulator of p53 reported to phosphorylate the same 
site (Ser 15) in ovarian carcinoma cells and in JB6 mouse epidermal cell line Cl 41, was also 
activated by paclitaxel treatment, but TAT-GESV did not reduce this activation. Our findings 
suggest that the TAT-GESV-induced reduction of pSer15-p53 may partly result from 
disruption of p38 MAPK activation but not from reduced activity of ERK1/2. However, 
more work is needed to investigate the role of p53 in contributing to pathogenesis of 
paclitaxel-induced neuropathic pain.
TAT-GESV also produced anti-allodynic efficacy in a model of traumatic nerve injury. 
Intrathecal TAT-GESV dose-dependently reduced mechanical and cold allodynia in the paw 
ipsilateral to PSNL but did not alter basal nociceptive responses in controls. Effects were 
similar to those produced by MK-801. PSNL also activates astrocytes and microglia in the 
lumbar spinal dorsal horn of rats [10; 32] and mice [52]. However, disagreement exists as to 
whether p38 MAPK activation in the lumbar spinal cord is produced by PSNL, although 
species differences and signal detection time may contribute to experimental differences 
observed [32; 33; 52]. PSNL also increased mRNA expression of chemokines C-C motif 
ligand 1 (CCL-1) in mouse spinal cord and dorsal root ganglion (DRG) and direct 
intrathecal injections of CCL-1 also induced phosphorylation of NR1 and NR2B and 
activated astrocytes and microglia in the lumbar spinal cord [2]. Thus, CCL-1 may be the 
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key mediator of tactile allodynia induced by PSNL, presumably via modulation of both glial 
cell activation and glutamate transmission [2]. More work is necessary to determine which 
cell types underlie the anti-allodynic efficacy of TAT-GESV in the PSNL model and whether 
TAT-GESV also acts indirectly to reduce glial cell activation. Notably, high dose TAT-GESV 
(10 nmol, i.t.) did not produce motor impairment or alter normal nociception (i.e. produce 
tail flick antinociception or sensitization). By contrast, MK-801 (25 nmol, i.t.) produced 
profound motor ataxia in the rotarod test. Therefore, anti-allodynic effects of TAT-GESV 
cannot be attributed to nonspecific disruption of motor function. More work is necessary to 
demonstrate that nNOS-NOS1AP disruptors exhibit a better therapeutic ratio compared to 
NMDAR antagonists and nNOS inhibitors using small molecule inhibitors that, unlike TAT-
GESV, can also be used systemically. Our findings collectively suggest that disruption of 
nNOS-NOS1AP protein-protein interactions represents a valuable therapeutic strategy for 
suppressing neuropathic pain without unwanted side effects associated with direct NMDAR-
blockade (Figure 10). Our studies also demonstrate that nNOS-NOS1AP interface is a 
previously unrecognized target for the development of anti-allodynic agents to treat 
neuropathic pain.
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Figure 1. 
TAT-GESV disrupts nNOS-NOS1AP but not PSD95-nNOS binding in AlphaScreen. A. 
TAT-GESV disrupted His-nNOS1-299 and GST-NOS1AP400-506 binding presented as 
%AlphaScreen Signal Counts with an IC50 of 8.47 μM. Neither TAT-GESVΔ1 nor TAT-
cp4GESV disrupted the binding between these two proteins under analogous conditions (n = 
4–9). B. TAT-GESV did not disrupt interactions between His-PSD951- 392 and GST-
nNOS1-299 under conditions in which the small molecule PSD95-nNOS inhibitor ZL006 
reliably disrupted this binding with an IC50 of 12.76 μM. Data are Mean ± S.D.
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Figure 2. 
The active but not the inactive nNOS-NOS1AP disruptor inhibits glutamate-induced cell 
death. Pretreatment with the active peptide TAT-GESV (10 μM) or the NMDAR antagonist 
MK-801 (20 μM) protected against cell death induced by glutamate (100 μM)/glycine (10 
μM) in primary cortical neurons relative to vehicle pre-treatment. Cell death was lower 
following pre-treatment with the active nNOS-NOS1AP disruptor TAT-GESV compared to 
the inactive peptide TAT-cp4GESV (10 μM) (see Figure 1 for binding data in AlphaScreen), 
and failed to protect against glutamate/glycine-induced cell death (n = 3–4). ***p < 0.001 
vs. vehicle and TAT-cp4GESV; xxxp < 0.001 vs. all groups except vehicle or TAT-cp4GESV; 
++p < 0.01 vs. TAT-GESV (One-way ANOVA followed by Bonferroni’s post hoc test). Data 
are Mean ± S.D.
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Figure 3. 
TAT-GESV, a peptide inhibitor of nNOS-NOS1AP interactions, suppressed paclitaxel-
induced mechanical and cold allodynia. A. Dosing and testing scheme used to evaluate the 
anti-allodynic efficacy of the nNOS-NOS1AP inhibitor in the paclitaxel model. Paw 
withdrawal threshold (g) was measured using an electronic von Frey anesthesiometer to 
assess mechanical sensitivity and duration (sec) of responding to acetone stimulation of the 
hindpaw was measured to assess cold sensitivity. Behavioral testing of mechanical and cold 
sensitivity was performed at time points shown by the thin arrows. Paclitaxel or vehicle was 
administered i.p. at time points indicated by the bold arrows. B, C. Paclitaxel lowered (B) 
mechanical paw withdrawal thresholds and increased (C) duration of cold responding 
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relative to cremophor-vehicle treatment in a time-dependent manner. Behavioral 
hypersensitivities were present beginning on day 7 and were ongoing throughout the 
observation interval. ***p < 0.0001 from Day 7–15 (Two-way repeated measures ANOVA 
followed by Bonferroni’s post hoc test). D, E. TAT-GESV dose-dependently (D) increased 
mechanical paw withdrawal thresholds and (E) reduced cold response times in paclitaxel-
treated mice. #p < 0.001 (paired sample t-test vs. baseline). *p < 0.05;**p < 0.01;***p < 
0.001 vs. corresponding vehicle: TAT-GESV group (Two-way ANOVA followed by 
Bonferroni’s post hoc test). The 5 nmol dose of TAT-GESV normalized responding to levels 
observed in mice receiving vehicle in lieu of paclitaxel. F, G. In paclitaxel-treated mice, 
TAT-GESV (10 nmol, i.t.) increased (F) mechanical paw withdrawal thresholds relative to 
both saline (i.t.) and TAT-GESVΔ1 (10 nmol, i.t.) treatment and lowered (G) cold response 
duration relative to saline (i.t.) treatment. *p < 0.05; **p < 0.01 (One-way ANOVA followed 
by Bonferroni’s post hoc test). Data are Mean ± S.E.M. (n = 6 per group).
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Figure 4. 
Duration of action of TAT-GESV-induced suppression of paclitaxel-induced mechanical 
allodynia. TAT-GESV (5 nmol i.t.) increased mechanical paw withdrawal thresholds relative 
to either saline (i.t.) or TAT-GESVΔ1 (5 nmol i.t.) treatment across the observation interval 
(p < 0.01 for each comparison). Anti-allodynic effects of TAT-GESV in paclitaxel-treated 
mice were time-dependent. **p < 0.01 vs. saline; ++p < 0.01; +++p < 0.001 vs. saline and 
TAT-GESVΔ1; #p < 0.01 vs. baseline for all groups (Two-way repeated measures ANOVA 
followed by Bonferroni’s post hoc test). Data are Mean ± S.E.M. (n = 5 per group).
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Figure 5. 
Intrathecal administration of TAT-GESV reduced phosphorylation of Ser15-p53 (pp53) 
levels induced by paclitaxel injection independent of the ERK1/2 pathway. A. In lumbar 
spinal cords derived from paclitaxel-treated mice, TAT-GESV (5 nmol, i.t.) reduced (A, C) 
p53 activation relative to saline (i.t.) but not TAT-GESVΔ1 (5 nmol, i.t.) (*p < 0.05 vs. 
saline; One way ANOVA followed by Bonferroni’s multiple comparison test). B, D. 
pERK1/2 was elevated in lumbar spinal cord derived from all paclitaxel-treated groups, but 
ERK1/2 activation was not blocked by TAT-GESV (i.t.). ***p < 0.001 vs. Vehicle: Saline 
(One-way ANOVA followed by Bonferroni’s post hoc test). Data are Mean ± S.E.M. (n = 5 
per group).
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Figure 6. 
Intrathecal administration of TAT-GESV, a peptide inhibitor of nNOS-NOS1AP, suppressed 
PSNL-induced mechanical and cold allodynia without affecting responses in the 
contralateral paw or in sham-operated mice. A. Surgery and testing scheme used to evaluate 
the anti-allodynic efficacy of nNOS-NOS1AP inhibitor in the PSNL model. Paw withdrawal 
threshold (g) was measured using an electronic von Frey anesthesiometer to assess 
mechanical sensitivity and duration (sec) of responding to acetone stimulation of the 
hindpaw was measured to assess cold sensitivity. Behavioral testing of mechanical and cold 
sensitivity was performed at time points shown by the thin arrows. PSNL or sham surgery 
was performed at time point indicated with the bold arrow. B, C. Mechanical (B) and cold 
(C) allodynia evoked by PSNL was dose-dependently suppressed by TAT-GESV. TAT-GESV 
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(5 and 10 nmol i.t.) normalized responding to levels observed in sham-operated mice 
receiving the same doses. #p < 0.001 vs. baseline (Paired sample t-test). **p < 0.01; ***p < 
0.001 vs. corresponding sham-operated group (Two-way ANOVA followed by Bonferroni’s 
post hoc test). D, E. In the paw ipsilateral to PSNL, TAT-GESV (10 nmol, i.t.) (D) increased 
mechanical paw withdrawal thresholds and (E) reduced duration of cold responding relative 
to either saline (i.t.) or TAT-GESVΔ1 (10 nmol, i.t.) treatment. *p < 0.05, **p < 0.01 vs. 
saline and TAT-GESVΔ1 (One-way ANOVA followed by Bonferroni’s post hoc test). F, G. 
TAT-GESV did not alter (F) mechanical paw withdrawal thresholds or (G) cold response 
time in the paw contralateral to PSNL or sham surgery (Two-way ANOVA). Data are Mean 
± S.E.M. (n = 6–10 per group).
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Figure 7. 
Repeated intrathecal dosing with the nNOS-NOS1AP inhibitor TAT-GESV (10 nmol, i.t.) 
suppressed PSNL-induced mechanical and cold allodynia without altering responses in the 
contralateral paw or in sham-operated mice. A, B. In mice subjected to PSNL, repeated once 
daily intrathecal injection of TAT-GESV (10 nmol i.t.) and MK-801 (5 nmol i.t.) across eight 
consecutive days elevated (A) mechanical paw withdrawal thresholds relative to saline and 
TAT-GESVΔ1 throughout the observation interval (p < 0.0001 for each comparison; Two-
way repeated measures ANOVA followed by Bonferroni’s post hoc test). Suppression of 
mechanical allodynia induced by TAT-GESV and MK-801 was also time-dependent. 
Repeated intrathecal injection of TAT-GESV reduced (B) duration of cold responses relative 
to saline (p < 0.0001) throughout the observation interval. Effects of TAT-GESV on PSNL-
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induced mechanical and cold allodynia were similar to MK-801. #p < 0.05 vs. baseline; *p < 
0.05 vs. saline; +++p < 0.001 vs. saline and TAT-GESVΔ1 (Two-way repeated measures 
ANOVA followed by Bonferroni’s post hoc test). C, D. TAT-GESV did not alter (C) 
mechanical paw withdrawal thresholds or (D) cold response time in the paw contralateral to 
PSNL. E–H. TAT-GESV did not alter responsiveness to mechanical or cold stimulation in 
either the (E,F) ipsilateral or (G,H) contralateral paw of sham-operated mice. A–H. Data was 
analyzed by Two-way repeated measures ANOVA followed by Bonferroni post hoc test. 
Data are Mean ± S.E.M. (n = 5–10 per group).
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Figure 8. 
Intrathecal injection of MK-801 (25 nmol, i.t.) but not TAT-GESV (10 nmol, i.t.) or TAT-
GESVΔ1 (10 nmol, i.t.) produced motor ataxia in the rota-rod test. MK-801 (25 nmol i.t.) 
reduced post-injection rota-rod descent latency relative to all other intrathecal treatments. *p 
< 0.05 vs. all post-injection groups (Two-way repeated measures ANOVA followed by 
Bonferroni’s post hoc test). Data are Mean ± S.E.M. (n= 4–8 per group).
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Figure 9. 
TAT-GESV at the highest dose assessed (10 nmol i.t.) did not produce antinociception or 
heat hypersensitivity in a radiant-heat tail flick test. Similar results were observed with 
MK-801 (5, 10 and 25 nmol i.t.). Post-injection tail-flick latencies differed from pre-
injection tail-flick latencies but this effect was not dependent upon intrathecal treatment. +p 
< 0.05 (Two-way repeated measures ANOVA). Data are Mean ± S.E.M. (n = 6–8 per group).
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Figure 10. 
Model depicting the proposed effect of the membrane-permeant peptide TAT-GESV on 
NMDAR signaling in neuropathic pain. NMDARs typically consist of two NR1 subunits and 
two NR2 subunits. The latter can interact via its C-terminus with the PDZ1 domain of the 
scaffolding protein postsynaptic density 95 kDa (PSD95), which tethers the enzyme 
neuronal nitric oxide synthase (nNOS) to the NMDAR, whereas the PDZ2 domain of PSD95 
is free to recruit nNOS via its β-finger (orange loop). Preceding the β-finger of nNOS is a 
canonical PDZ domain that recruits NOS1AP, an adaptor protein that recruits the p38 
MAPK activator MKK3 and mediates nNOS-dependent activation of p38MAPK activity 
[29] (left panel). Activation of p38 MAPK leads to phosphorylation of its substrates such as 
serine 15 on p53, which in this study is used as a surrogate marker of p38 MAPK activation. 
We propose that this pathway mediates the contribution of NMDAR-nNOS signaling to 
central sensitization and chronic pain. We postulate that TAT-GESV (right panel) displaces 
NOS1AP from the PDZ domain of nNOS, uncoupling the p38 MAPK-p53 pathway from the 
NMDAR-PSD95-nNOS complex, thereby reducing central sensitization and chronic pain.
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